

Index

A acid-base management DHCA, 132–3 acid-base status during CPB, 74–5 acidosis. <i>See</i> metabolic acidosis; respiratory acidosis activated clotting time (ACT), 43, 47, 61 acute ischemia during CPB, 89 acute kidney injury (AKI), 167–74 acute tubular necrosis (ATN), 170 definitions, 167–8 effects of endotoxins, 171 effects of SIRS, 171 etiology, 170–1 hyperkalemia therapy, 173 hypo- and hypernatremia therapy, 173 hypoxia and renal damage, 170 incidence, 167 management of dialysis- dependent patients, 172 management of patients with non-dialysis-dependent CKD, 172 oliguria therapy, 173 outcomes associated with, 168 prevention strategies, 171–2 renal replacement therapy, 173–4 risk factors for, 169–70 therapy for AKI, 172–4 acute pulmonary embolism use of CPB, 192 acute respiratory distress syndrome (ARDS) post-CPB, 150–1 acute respiratory failure use of CPB, 192 acute tubular necrosis (ATN), 170 adrenaline (epinephrine), 103 alarm systems	CPB monitoring, 20 re-enabling before weaning from CPB, 96 albumin, 39 alkalosis metabolic, 74–5 respiratory, 75 alpha-stat management of blood gas, 75, 132–3 ε-aminocaproic acid (EACA), 50–1, 131 anesthesia for DHCA, 126–8 weaning from CPB, 95 analgesia weaning from CPB, 95 antegrade cerebral perfusion (ACP), 74 antegrade delivery of cardioplegia, 84–5 anti-thrombin III (AT-III) deficiency, 43, 61 anticoagulation during CPB, 41–52 activated clotting time (ACT), 47 argatroban, 45 bivalrudin, 45 coagulation cascade, 41 danaproid, 44–5 dangers of clot formation, 41 direct thrombin inhibitors, 45 fibrinolytics, 45 heparin, 42–4 heparin neutralization, 45–7 lepirudin, 45 low-molecular-weight heparin (LMWH), 44 monitoring anticoagulation in the operating room, 47–8 pharmacological strategies, 42–5 point of care (POC) testing, 47–8 transfusion algorithms, 52 anticoagulation reversal, 45–7 weaning from CPB, 94, 101–2	antifibrinolytic agents, 50–1, 131 aorta. <i>See</i> thoracic aorta aortic root replacement cardioplegia, 89–90 aprotinin, 51, 131 ARDS (acute respiratory distress syndrome) post-CPB, 150–1 argatroban, 45 arterial blood analysis, 78–9 arterial blood gases weaning from CPB, 97 arterial cannulae, 3–5 arterial cannulation, 54–7 ascending aorta, 55 axillary artery, 57 cannula types, 54–5 complications of aortic root cannulation, 55–6 connection to the patient, 55 femoral artery, 55–6 innominate artery, 55 performance index of an arterial cannula, 54 peripheral arterial cannulation, 56–7 presence of atherosclerosis, 55 subclavian artery, 55 arterial line filters, 13–4, 23 ascending aorta arterial cannulation, 3–5 autologous priming of the CPB circuit, 37, 71 AVR surgery, 58
		B bicarbonate buffer system, 74 bicaval cannulation, 6, 58 bivalrudin, 45 bleeding after CPB patient management, 51–2 bleeding prevention ε-aminocaproic acid, 50–1 antifibrinolytic agents, 50–1 aprotinin, 51 desmopressin, 51 heparin dosing, 51

Index

- bleeding prevention (*cont.*)
 - non-pharmacological strategies, 51
 - protamine dosing, 51
 - tranexamic acid, 50–1
 - blood-based priming solutions, 37
 - blood cardioplegia. *See* cardioplegia
 - blood flow, cessation. *See* deep hypothermic circulatory arrest (DHCA)
 - blood gas management
 - DHCA, 132–3
 - during CPB, 75–6
 - blunt thoracic aortic injury, 190–1
 - brain injury. *See* cerebral morbidity in adult cardiac surgery
 - bubble traps and filters, 13–4
 - buffer systems, 74
- C
- CABG (coronary artery bypass graft), 6, 58
 - comparison of CPB and OPCAB, 151
 - See also* OPCAB.
 - calcium
 - Ca²⁺ electrolyte, 76
 - in cardioplegia solutions, 82
 - carbon dioxide level in the patient's blood, 75–6
 - cardiac function assessment
 - weaning from CPB, 95
 - cardiac surgery
 - de-airing the heart, 97
 - cardioplegia, 80–90
 - acute ischemia, 89
 - acute MI/arrest cardioplegia, 89
 - alternatives to, 86–7
 - antegrade delivery, 84–5
 - aortic root replacement, 89–90
 - blood cardioplegia, 82–4
 - components of cardioplegia solutions, 81–4
 - definition, 80
 - delivery systems, 84
 - evolving myocardial infarction, 89
 - goals and principles of myocardial protection, 81–2
 - integrated method of administration, 87–9
 - modifications for particular situations, 89–90
 - monitoring distribution by temperature, 86
 - myocardial damage during CPB, 80
 - optimum cardioplegia technique, 87–9
 - prevention of septal dysfunction, 89
 - retrograde delivery, 84–5
 - routes of cardioplegia delivery, 84–6
 - temperature of the cardioplegia solution, 86
 - cardioplegia delivery systems, 15–7, 23, 84
 - cardioprotective strategies. *See* cardioplegia
 - cardiopulmonary bypass (CPB)
 - definition, 1
 - history of development, 1
 - modifications for DHCA, 129–30
 - rates of patient injury or death, 28
 - versus OPCAB, 148
 - cardiopulmonary bypass circuit
 - reducing priming volume, 70
 - cardiopulmonary bypass circuit assembly, 23–8
 - approaches to the setup procedure, 23–5
 - disposable items, 23
 - pre-bypass checklist, 25
 - priming solutions, 36–40
 - review of patient's notes, 25
 - safety issues, 23, 25, 28
 - cardiopulmonary bypass circuit primes. *See* priming solutions for CPB circuits
 - cardiopulmonary bypass in non-cardiac procedures, 187–96
 - blunt thoracic aortic injury, 190
 - emergency cardiopulmonary support (ECPS), 195–6
 - liver transplantation, 193
 - management of acute pulmonary embolism, 192
 - management of acute respiratory failure, 192
 - rewarming from severe hypothermia, 190–2
 - single and double lung transplantation, 192–3
 - thoracic aortic aneurysms, 189–90
 - thoracic aortic dissection, 187–8
 - thoracic aortic surgery, 187–90
 - trauma care, 194–5
 - tumor resection, 193–4
 - cardiopulmonary bypass machine
 - basic circuit, 1
 - cardiopulmonary bypass procedure, 54–67
 - adequate tissue perfusion, 62–4
 - arterial cannulation, 54–7
 - cardiotomy suction, 59
 - central venous pressure (CVP), 64
 - electrocardiogram (ECG), 64
 - general management, 61–6
 - hemodilution, 63
 - hypothermic CPB, 65
 - laboratory investigations, 66
 - left atrial (LA) pressure, 64
 - mean arterial pressure (MAP), 63–4
 - multidisciplinary approach, 54
 - planning, 54
 - pulmonary artery (PA) pressure, 64
 - recommended flow rates for CPB, 62–3
 - systemic oxygen delivery (DO₂), 62–3
 - systemic oxygen demand (VO₂), 62–3
 - temperature, 65
 - termination of CPB, 66–7
 - transition of patient onto CPB, 61–2
 - transesophageal echocardiography (TOE), 65–6
 - urine volume, 65
 - venous cannulation and drainage, 57–8
 - venting the heart, 60–1
 - weaning from CPB, 66–7
 - cardiothoracic surgery
 - optimal surgical field, 1
 - cardiotomy reservoir, 8–9
 - cardiotomy suction, 59
 - adverse effects, 59

- cavitation in roller pumps, 8
 - cavitation in venous drainage, 57
 - cavo-atrial cannulation, 58
 - central venous pressure (CVP) during CPB, 64
 - centrifugal pumps, 8
 - cerebral morbidity in adult cardiac surgery, 153–66
 - cerebral physiology during CPB, 153–6
 - determinants of cerebral perfusion, 153–6
 - effects of glucose control, 157
 - effects of perfusion pressure, 156
 - effects of temperature, 156–7
 - intraoperative ischemia and physiological management, 156–7
 - neurocognitive outcomes, 163–6
 - neurological complications, 153
 - OPCAB and stroke, 159
 - perioperative stroke, 157–8
 - risk factors for perioperative stroke, 161–3
 - stroke and OPCAB, 159
 - stroke risk in the general population, 161–3
 - timing of cardiac surgery-related stroke, 159–60
 - cerebral perfusion during CPB, 153–6
 - cerebral physiology during CPB, 153–6
 - cerebral substrate delivery monitoring, 135–6
 - chest splinting, 105
 - children
 - priming solutions for CPB circuits, 36
 - chloride ions in cardioplegia solutions, 82
 - chronic kidney disease (CKD), 167, 169, 171
 - management of dialysis-dependent patients, 172
 - management of non-dialysis-dependent patients, 172
 - circulating volume
 - weaning from CPB, 94
 - citrate phosphate dextrose (CPD) in cardioplegia solutions, 82, 87
 - Clot Signature Analyzer, 48
 - clotting and platelet function assessment
 - weaning from CPB, 94
 - coagulation
 - weaning from CPB, 94
 - coagulation cascade, 41
 - activation of the extrinsic pathway, 52
 - coagulation disorders after CPB, 49–52
 - antifibrinolytic agents, 50–1
 - causes, 49–50
 - effects of hypothermia, 50
 - fibrinolysis, 50
 - heparin rebound, 50
 - management of the bleeding patient, 51–2
 - platelet abnormalities, 49–50
 - prevention of bleeding, 50–1
 - SIRS, 50
 - Cobe Duo membrane oxygenator, 13
 - colloid-based priming solutions, 39–40
 - complement system
 - role in organ damage during CPB, 143
 - contact activation, 142–4
 - coronary artery bypass graft. *See* CABG
 - CPB. *See* cardiopulmonary bypass
 - CPD in cardioplegia solutions, 82, 87
 - cross-circulation technique, 1
 - crystalloid priming solutions, 37–9
- D**
- danaparoid, 44–5
 - deep hypothermic circulatory arrest (DHCA), 55, 73–4, 125–38
 - acid–base management, 132–3
 - alpha-stat blood gas management, 132–3
 - anesthesia, 126–8
 - applications, 125
 - blood gas management, 132–3
 - cerebral substrate delivery monitoring, 135–6
 - cooling, 129
 - CPB modifications, 129–30
 - duration of circulatory arrest, 129
 - extracorporeal circulation, 129–30
 - glycemic control, 134
 - hemodilution, 132
 - hemostasis, 131
 - history of development, 125–6
 - hypothermia
 - neuroprotection, 131–2
 - leukocyte depletion, 134
 - neurological function monitoring, 136–7
 - neurological monitoring, 135–7
 - neuroprotection strategies, 131–7
 - outcome, 137–8
 - pathophysiology of hypothermia, 126
 - pH-stat blood gas management, 132–3
 - pharmacological neuroprotection, 135
 - postoperative care, 137
 - practical considerations, 126–31
 - preoperative assessment, 126
 - preservation of organ function, 125
 - retrograde cerebral perfusion (RCP), 133
 - re-warming, 130
 - safe duration of DHCA, 129–30
 - selective antegrade cerebral perfusion (SACP), 133–4
 - spinal cord protection, 135
 - surgical considerations, 128
 - temperature monitoring, 127–8
 - desmopressin, 52
 - bleeding prevention, 51
 - dextrans, 39
 - direct thrombin inhibitors, 45
 - disseminated intravascular coagulation (DIC), 41
 - DO₂. *See* systemic oxygen delivery
 - dobutamine, 103
 - drainage
 - venous, 57
 - drug dilution and loss during CPB, 78

Index

E

ECMO. *See* extracorporeal membrane oxygenation
electrocardiogram (ECG) recording during CPB, 64
electrolytes, 76–8
 monitoring, 78–9
 weaning from CPB, 66
emergency cardiopulmonary support (ECPS), 195–6
endothelium
 functions during CPB, 144
endotoxins
 and acute kidney injury, 171
 produced during CPB, 146
enoxinone, 103
epicardial pacing, 98–9
equipment
 alarm systems, 20
 arterial and venous saturation monitors, 18–9
 arterial cannulae, 3–5
 arterial line filters, 13–4, 23
 cardioplegia delivery systems, 15–7, 23
 centrifugal pumps, 8
 filters and bubble traps, 13–4
 gas supply system, 13
 hemofilters, 17–8
 history of development, 1
 in-line blood gas analyzers, 18–9
 oxygenators, 10–3, 23
 pumps, 6–8
 reservoirs, 8–9, 23
 roller pumps, 7–8
 suckers and vents, 14–5
 tubing, 1–3, 23
 venous cannulae, 6
extracorporeal membrane oxygenation (ECMO), 176–86
 cannulation, 183
 cardiac ECMO in adults, 179
 differences to CPB, 176
 history of development, 176
 indications, 176–9
 inflammatory response to, 183
 patient management, 183–5
 respiratory ECMO in adults, 177–9
 types of ECMO, 176
 veno-arterial (VA) ECMO, 176–7

 veno-arterial (VA) ECMO cannulation, 183
 veno-arterial (VA) ECMO weaning and decannulation, 185–6
 veno-venous (VV) ECMO, 176–7
 veno-venous (VV) ECMO cannulation, 183
 veno-venous (VV) ECMO weaning and decannulation, 185
extracorporeal membrane oxygenation (ECMO) circuit, 181, 179–83
 anticoagulation, 183
 bridge, 182
 cannulae, 179–81
 heat exchanger, 182
 monitoring, 182
 oxygenators, 182
 pump, 181–2
 safety devices, 182

F

femoral veins
 cannulation, 6
fibrillatory arrest with hypothermia
 myocardial protection method, 86–7
fibrinolysis
 after CPB, 52
 in the CPB circuit, 50
fibrinolytic pathway, 144
fibrinolytics, 45
Fick equation, 62
Fick's Law of Diffusion, 10
filters and bubble traps, 13–4
flow rates during CPB, 72
functional mitral regurgitation, 104

G

gas-exchange mechanisms
 oxygenators, 10–3
gas supply system, 13
gastrointestinal complications of CPB, 148
gelifusine, 39
Gibbon, John, 1, 187
glucose
 serum glucose levels, 77
glucose control

 effects on neurological outcome, 157
 weaning from CPB, 77
glycemic control during DHCA, 134

H

Hartmann's solution, 38
heart-lung transplant, 58
heart transplant, 58
hematocrit (HCT)
 effects of hemodilution, 70–1
hematocrit monitors, 18–9
hemoconcentrators, 17–8
hemodilution, 63
 during DHCA, 132
 metabolic management during CPB, 70–1
hemofilters, 17–8
hemofiltration, 77–8, 146
hemoglobin
 buffering of hydrogen ions, 74
hemoglobin concentration
 weaning from CPB, 94
Hemochron, 47
hemophilia, 51–2
HemoTec ACT, 47
heparin, 42–4
heparin (unfractionated, UFH)
 ACT monitoring, 43
 dosing, 43
 heparin-induced thrombocytopenia (HIT), 43–4
 heparin resistance, 43
 mechanism of anticoagulant action, 42–3
 monitoring, 43
 structure, 42
 use as CPB anticoagulant, 42–4
heparin-bonded circuitry, 146
heparin dosing
 bleeding prevention, 51
heparin-induced platelet activation assay (HIPPA), 44
heparin-induced thrombocytopenia, 43–4
Heparin Management Test (HMT) Cascade analyzer, 47
heparin neutralization, 45–7
 heparinase, 47
 hexadimethrine, 46
 methylene blue, 46–7
 omit neutralization, 47

- platelet factor 4 (PF4), 46
 - protamine, 45–6
 - heparin rebound, 50
 - heparin resistance, 43, 61
 - heparinase, 47
 - hepatic dysfunction caused by CPB, 148–9
 - Hepcon HMS® analyzer, 47
 - hexadimethrine
 - heparin neutralization, 46
 - High-Dose Thrombin Time (HiTT), 47
 - hydroxyethyl starch, 39
 - hyperkalemia, 93
 - therapy for AKI, 173
 - hyponatremia
 - therapy for AKI, 173
 - hypokalemia, 93
 - hyponatremia
 - therapy for AKI, 173
 - hypoperfusion during CPB, 72
 - hypothermia, 70
 - blood gas management, 75
 - DHCA, 73–4
 - during CPB, 65, 72–3
 - effects on hemostasis, 50
 - pathophysiology, 126
 - hypothermia (accidental)
 - re-warming from severe hypothermia, 190–2
 - hypoxia and renal damage, 170
- I**
- in-line blood gas analysis, 18–9, 78–9
 - inferior vena cava cannulation, 6
 - inflammatory response to ECMO, 183
 - inorganic phosphate buffers, 74
 - inotropic drugs, 94–5
 - inotropic support
 - weaning from CPB, 99–100
 - 102–3
 - integrated method of cardioplegia administration, 87–9
 - intra-aortic balloon
 - counterpulsation, 106–8
 - complications, 108
 - description of the IABP, 106
 - effects on cardiovascular physiology, 106
 - IABP placement, 106
 - management of the IABP patient, 106–8
 - intra-aortic balloon pump (IABP), 105
 - description, 106
 - placement, 106
 - intraoperative ischemia and physiological management, 156–7
 - ischemia–reperfusion injury (IRI), 144–5
- J**
- Jehovah's Witness patients, 35, 71
- K**
- Kay, Philip, 23
 - kinin–kallikrein pathway, 143–4
- L**
- laboratory investigations, 66
 - lactate
 - serum lactate levels, 77, 94
 - lactated Ringer's solution, 38
 - latex tubing in the CPB circuit, 3
 - Lee-White clotting time. *See* activated clotting time
 - left atrial (LA) pressure during CPB, 64
 - left ventricular assist device (LVAD), 109
 - lepirudin, 45
 - leukocyte depletion, 146–7
 - during DHCA, 134
 - levosimendan, 103
 - liver transplantation
 - use of extracorporeal circulation, 193
 - low-molecular-weight heparin (LMWH), 44
 - lung transplantation
 - use of CPB, 192–3
- M**
- magnesium
 - in cardioplegia solutions, 82, 87
 - Mg⁺ electrolyte, 77
 - magnesium level
 - weaning from CPB, 93, 97
 - mannitol
 - in cardioplegia solutions, 87
 - use in CPB primes, 39–40
 - mean arterial pressure (MAP), 63–4
 - mechanical circulatory support, 106–24
 - history of development, 106
 - intra-aortic balloon counterpulsation, 106–8
 - range of options, 106
 - ventricular assist devices (VADs), 108–24
 - mechanical ventilation
 - weaning from CPB, 96
 - metabolic acidosis, 38–9, 72, 74–5
 - weaning from CPB, 94, 97
 - metabolic alkalosis, 74–5
 - metabolic management during CPB, 70–8
 - acid-base status, 74–5
 - alpha-stat management of blood gas, 75
 - autologous priming of the CPB circuit, 71
 - blood gas management, 75
 - causes of metabolic derangement, 70
 - DHCA, 73–4
 - drug dilution and loss, 78
 - electrolytes, 76–8
 - flow rates, 72
 - hemodilution, 70–1
 - hemofiltration, 77–8
 - hypoperfusion, 72
 - hypothermia, 72–4
 - metabolic effects of CPB primes, 70–1
 - monitoring of patient parameters, 78–9
 - pH, 74–5
 - pH-stat management of blood gas, 75
 - principles, 70
 - temperature effects, 72–4
 - methylene blue
 - heparin neutralization, 46–7
 - milrinone, 103
 - mini-bypass, 20–2
 - monitoring during CPB, 18–20
 - Munsch, Christopher, 23
 - myocardial damage
 - causes during CPB, 80
 - postoperative detection methods, 80
 - myocardial dysfunction
 - associated with CPB, 151
 - myocardial infarction during CPB, 89
 - myocardial protection during CPB, 80–90

Index

- myocardial protection during CPB (*cont.*)
acute ischemia, 89
acute MI/arrest cardioplegia, 89
alternatives to cardioplegia, 86–7
antegrade delivery of cardioplegia, 84–5
aortic root replacement, 89–90
cardioplegia delivery systems, 84
cardioplegia technique modifications, 89–90
causes of myocardial damage, 80
components of cardioplegia solutions, 81–4
definition of cardioplegia, 80
evolving myocardial infarction, 89
fibrillatory arrest with hypothermia, 86–7
goals and principles, 80–1
integrated method of cardioplegia administration, 87–9
monitoring cardioplegia distribution by temperature, 86
optimum cardioplegia technique, 87–9
postoperative detection of myocardial damage, 80
prevention of septal dysfunction, 89
retrograde delivery of cardioplegia, 84–6
routes of cardioplegia delivery, 84–6
surgical septum, 89
temperature of the cardioplegia solution, 86
- N**
neurocognitive outcomes in cardiac surgery, 163–6
neurological complications in adult cardiac surgery, 153
neurological function monitoring during DHCA, 136–7
neurological monitoring during DHCA, 135–7
- neuromuscular blockade weaning from CPB, 95
neuroprotection strategies during DHCA, 131–7
non-bicarbonate buffers, 74
non-pulsatile (laminar) flow during CPB, 8
Normal Saline solution, 38
Normosol solution, 38
NovoSeven (recombinant factor VIIa), 52
- O**
oliguria therapy for AKI, 173
OPCAB (off-pump CABG), 47, 55, 140
and stroke, 159
comparison with CPB, 148, 151
organ damage during CPB, 140–51
activation of plasma protease pathways, 142–4
alterations in organ perfusion, 148
comparison with OPCAB, 151
complement activation, 143
contact activation, 142–4
CPB versus OPCAB, 148
endotoxins, 146
fibrinolytic pathway, 144
gastrointestinal complications, 148
hepatic dysfunction, 148–9
ischemia–reperfusion injury (IRI), 144–5
myocardial dysfunction, 151
pancreatitis, 149–50
post-CPB ARDS, 150–1
pulmonary dysfunction, 150–1
quality of life after cardiac surgery, 151
role of the endothelium, 144
role of the kinin–kallikrein pathway, 143–4
SIRS, 146–7
therapeutic strategies, 146–7
triggers of organ damage, 140
See also acute kidney injury (AKI); cerebral morbidity in adult cardiac surgery
oxygen delivery. *See* systemic oxygen delivery (DO₂)
oxygen demand. *See* systemic oxygen demand (VO₂)
oxygen-hemoglobin dissociation curve, 73
oxygenators, 10–3, 23
oxyhemoglobin buffering of hydrogen ions, 74
- P**
pancreatitis related to CPB, 149–50
paradoxical intracellular acidosis weaning from CPB, 97
patient injury or death rates for CPB, 28
patient management bleeding after CPB, 51–2
patient's notes review prior to CPB circuit assembly, 25
perfusion during CPB pulsatile versus non-pulsatile (laminar) flow, 8
perfusion pressure effects on neurological outcome, 156
perioperative stroke, 157–8
pH bicarbonate buffer system, 74
buffer systems, 74
during CPB, 74–5
non-bicarbonate buffers, 74
normal pH of arterial blood, 74
pH-stat management of blood gas, 75, 132–3
pharmacology anticoagulation strategies, 42–45
interventions for SIRS, 146
neuroprotection during DHCA, 135
phosphate electrolyte, 77
physiological alarms CPB monitoring, 20
re-enabling before weaning from CPB, 96
Plasma-Lyte solution, 38
plasma protease pathways activation, 142–4
plasma proteins buffering capacity, 74
effects of hemodilution, 71
platelet factor 4 (PF4)

- heparin neutralization, 46
- platelet function
 - abnormalities after CPB, 49–50, 52
 - point of care (POC) tests, 48
- Platelet Function Analyzer, PFA-100, 48
- platelet-rich plasma (PRP)
 - aggregation assay, 44
- platelet transfusion, 52
- Plateletworks, 48
- point-of-care (POC) testing, 47–8
 - and transfusion algorithms, 52
- post-CPB ARDS, 150–1
- potassium
 - in cardioplegia solutions, 82, 87
 - K⁺ electrolyte, 76
- potassium level
 - weaning from CPB, 93
- pre-bypass checklist
 - design and use of, 25
- priming solutions for CPB
 - circuits, 36–40
 - acceptable hemodilution, 36–7
 - association with metabolic acidosis, 38–9
 - autologous priming, 37
 - avoiding allogenic blood transfusions, 37
 - blood-based primes, 37
 - children, 36
 - colloid-based primes, 39–40
 - crystalloid primes, 37–9
 - experimental oxygen-carrying solutions, 40
 - Hartmann's solution, 38
 - infants and neonates, 36
 - Lactated Ringer's solution, 38
 - mannitol, 39–40
 - metabolic effects, 70–1
 - Normal Saline solution, 38
 - Normosol solution, 38
 - Plasma-Lyte solution, 38
 - prime volume, 36–7
 - purpose of priming solution, 36
 - Ringer's solution, 38
 - target hematocrit, 36–7
 - tonicity of the priming solution, 37–8
 - types of priming solution, 37–40
 - Procaïne in cardioplegia solutions, 82
 - protamine
 - heparin neutralization, 45–6
 - protamine dosing
 - bleeding prevention, 51
 - pulmonary artery (PA) pressure during CPB, 64
 - pulmonary dysfunction
 - associated with CPB, 150–1
 - pulsatile flow during CPB, 8
 - pumps used in extracorporeal circuits, 7–8
 - PVC tubing, 1–3

Q

 - quality of life after cardiac surgery, 151

R

 - recombinant factor VIIa (rFVIIa), 52
 - renal damage. *See* acute kidney injury (AKI); chronic kidney disease (CKD)
 - renal replacement therapy for AKI, 173–4
 - reservoirs, 23
 - venous, 8–9
 - respiratory acidosis, 75
 - respiratory alkalosis, 75
 - retrograde cerebral perfusion (RCP), 74
 - DHCA, 133
 - retrograde delivery of cardioplegia, 84–6
 - right ventricular assist device (RVAD), 109
 - Ringer's solution, 38
 - roller pumps, 7–8

S

 - safety issues
 - before, during and after CPB, 25
 - rates of patient injury or death, 28
 - salvaged blood, 9
 - suckers and vents, 14–5
 - weaning from CPB, 94
 - See also* cardiotomy suction.
 - selective antegrade cerebral perfusion (SACP)
 - DHCA, 133–4
 - septal dysfunction after cardiac surgery, 89
 - serotonin release assay (SRA), 44
 - silicone rubber tubing in the CPB circuit, 3
 - SIRS (systemic inflammatory response syndrome), 50, 64, 140–2, 146–7
 - and acute kidney injury, 171
 - sodium in cardioplegia solutions, 82
 - Sonoclot test, 48
 - spinal cord
 - protection during DHCA, 135
 - reducing ischemia during descending aneurysm surgery, 189
 - St Thomas' Hospital cardioplegia solution, 82
 - stroke
 - and intraoperative physiological management, 156–7
 - and OPCAB, 159
 - perioperative, 157–8
 - risk factors for perioperative stroke, 161–3
 - stroke risk in the general population, 161–3
 - timing of cardiac surgery-related stroke, 159–60
 - suckers and vents, 14–5
 - superior vena cava cannulation, 6
 - surgical septum, 89
 - S_vO₂ measurement, 78–9
 - systemic inflammatory response syndrome (SIRS), 50, 64, 140–2, 146–7
 - and acute kidney injury, 171
 - systemic oxygen delivery (DO₂)
 - blood gas monitoring, 78–9
 - influence of temperature, 72–3
 - metabolic acidosis, 74–5
 - systemic oxygen demand (VO₂)
 - blood gas monitoring, 78–9
 - influence of temperature, 72–3
 - metabolic acidosis, 74–5
 - systemic vascular resistance (SVR), 100–1

Index

T

temperature
 during CPB, 64–5, 72–3
 effects on neurological outcome, 156–7
 influence on blood gas management, 75
 weaning from CPB, 92–3
Terumo CDI-500 in-line blood gas analyzer, 19
THAM in cardioplegia solutions, 82, 87
thoracic aorta, blunt injury, 190
thoracic aortic aneurysms, 188–9
thoracic aortic dissection, 187–8
thoracic aortic surgery, 187–90
thrombocytopenia
 after CPB, 52
 heparin-induced (HIT), 43–4
thromboelastography (TEG), 48
 alpha angle, 48
 clot lysis measurement, 48
 K value, 48
 MA (maximum amplitude), 48
 R value, 48
tissue plasminogen activator (tPA), 144
tonicity of a priming solution, 37–8
total artificial heart (TAH), 106
total circulatory arrest. *See* deep hypothermic circulatory arrest (DHCA)
tranexamic acid, 50–1, 131
transfusion algorithms, 52
transesophageal echocardiography (TOE)
 during CPB, 65–6
 role in weaning from CPB, 101
trauma care
 use of CPB, 194–5
tromethamine (tris-hydroxymethyl aminomethane). *See* THAM
tubing in the CPB circuit, 1–3, 23
tumor resection
 use of CPB, 193–4

U

ultrafilters, 17–8
ultrafiltration, 77–8, 146

uninterruptible power supply (UPS), 23
urine volume during CPB, 65

V

vasoactive drugs, 94–5, 102–3
vasodilators, 94–5
vasopressors, 94–5, 102–3
venous and arterial oxygen saturation monitors, 18–9
venous blood analysis, 78–9
venous cannulae, 6
venous cannulation and drainage, 57–8
 avoiding air entry into the system, 58
 cavitation phenomenon, 57
 cavo-atrial cannulation, 58
 connection to the patient, 57–8
 peripheral venous cannulation, 58
 right atrial cannulation, 57–8
 single cannula approach, 57
 types and sizes of cannulae, 57
 venous drainage, 57
venous circulation and drainage
 bicaval cannulation, 58
venting the heart, 14–5, 60–1
 venting methods, 61
 venting the left heart, 60
 venting the right heart, 60–1
ventricular assist devices (VADs), 105, 108–24
 bridge to recovery (BTR), 110–1
 bridge to transplant (BTT), 110–1
 categories of potentially suitable patients, 111–3
 continuous flow devices, 113
 decision-making process, 111–3
 description, 109
 destination therapy (DT), 110–1
 factors affecting output, 110
 HeartMate II, 116–8
 left ventricular assist device (LVAD), 109
 Levitronix CentriMag, 114

long-term care of VAD patients, 123–4
outcomes for patients, 110–1
patient management, 120–3
perioperative patient management, 120–2
postoperative patient management, 122–3

preoperative patient management, 120
pulsatile devices (volume displacement devices), 113
purpose of VADs, 108–9
right ventricular assist device (RVAD), 109
Thoratec PVAD and IVAD, 114–6
types of VAD, 120
types of VAD systems, 110
Ventracor VentrAssist, 120
weaning from CPB with VAD support, 122
Verify Now monitoring system, 48
VO₂. *See* systemic oxygen demand
von Willebrand factor (VWF), 51, 52

W

weaning from CPB, 66–7, 92–105
 adrenaline (epinephrine), 103
 analgesia, 95
 anesthesia, 95
 arterial blood gases, 97
 assessment and adjustment of preload, 99
 assessment of afterload, 100–1
 assessment of clotting and platelet function, 94
 assessment of contractility, 99–100
 calcium level, 93
 cardiac function assessment, 95
 chest splinting, 105
 circulating volume, 94
 coagulation, 94
 de-airing the heart, 97

Index

dobutamine, 103	inotropic support, 99–100, 102–3	re-institution of CPB, 92
dopamine, 103	intra-aortic balloon	re-warming the patient, 92–3
electrolytes, 97	counterpulsation, 105	reversal of anticoagulation, 94, 101–2
enabling physiological alarms, 96	lactate levels, 94	role of TOE, 101
enoximone, 103	levosimendan, 103	systemic vascular resistance (SVR), 100–101
epicardial pacing, 98–9	magnesium levels, 93, 97	temperature of the patient, 92–3
events immediately prior to, 98	mechanical support, 104–5	use of salvaged blood, 94
failure to achieve satisfactory weaning, 102–5	mechanical ventilation, 96	vasoactive drugs, 94–5, 102–3
functional mitral regurgitation, 104	mechanics of separation from CPB, 99–101	vasodilators, 94–5
glucose control, 93	metabolic acidosis, 94, 97	vasopressors, 94–6, 102–3
hemoglobin concentration, 94	milrinone, 103	ventricular assist devices (VADs), 105
hyperkalemia, 93	neuromuscular blockade, 95	with VAD support, 122
hypokalemia, 93	paradoxical intracellular acidosis, 97	
inotropic drugs, 94–5, 96	potassium level, 93	
	predicting difficulty, 95–6	
	preparation, 92–6	